Brief Summary
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).
Intervention / Treatment
- Biological: Sacituzumab Govitecan
- Biological: Pembrolizumab
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC)
- Has confirmation that epidermal growth factor receptor (EGFR), anaplastica term used to describe abnormal cancer cells that grow uncontrollably in the body and have little or no resemblence to regular cells lymphoma kinase 1 (ALK-1), or ROS proto-oncogene 1 (ROS-1)-directed therapy is not indicated as primary therapy
- Has provided tumor tissue that demonstrates PD-L1 tumor proportion score (TPS) ≥50% of tumor cells as assessed by immunohistochemistry (IHC) at a central laboratory
- Has a life expectancy of at least 3 months